Abstract

In their recently published article (a sub-study of UNIVERSE), Ashton E et al. explored potential adverse effects of rosuvastatin including effects on plasma coenzym Q10 (CoQ) levels and collagen turnover in patients with chronic heart failure (CHF) [1], and tried to explain why high dose rosuvastatin failed to improve cardiac remodelling in CHF in the UNIVERSE study [2]. I agree with the authors that increased collagen turnover and decreased plasma CoQ levels due to rosuvastatin therapy might have negatively influenced cardiac remodelling [1].

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call